CoChat

Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis

Open access
Reich, Nicole, Tomcik, Michal, Zerr, Pawel, Lang, Veronika, Dees, Clara, Avouac, Jérome, Palumbo, Katrin, Horn, Angelika, Akhmetshina, Alfiya, Beyer, Christian, Xie, Weilin, Bennett, Brydon L, Distler, Oliver, Schett, Georg, Distler, Jörg H W · 2012 · Annals of the Rheumatic Diseases
Cited by 60

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Objectives The hallmark of systemic sclerosis (SSc) is the accumulation of extracellular matrix proteins by pathologically activated fibroblasts. This study analysed the antifibrotic effects of the selective c-Jun N-terminal kinase (JNK) inhibitor, CC-930, which recently entered first clinical trials as a novel antifibrotic approach. Methods Phosphorylated c-Jun was detected by western blot and immunohistochemistry. The model of bleomycin-induced dermal fibrosis and the tight skin 1 (TSK1) mouse model were used to investigate the effects of CC-930 on the prevention of experimental fibrosis. The potential of CC-930 to induce regression of fibrosis was assessed in a modified model of established fibrosis. Results Transforming growth factor beta (TGFβ) and platelet-derived growth factor (PDGF) activate JNK and stimulate the phosphorylation of its downstream target c-Jun. Incubation with CC-930 prevented the phosphorylation of c-Jun and reduced the stimulatory levels of these cytokines on the release of collagen. Inhibition of JNK prevented dermal thickening, myofibroblast differentiation and the accumulation of collagen in a dose-dependent manner in mice challenged with bleomycin and in TSK1 mice. In addition to the prevention of fibrosis, treatment with pharmacologically relevant doses of CC-930 also induced regression of established experimental fibrosis. Conclusions These data identify JNK as a downstream mediator of the pro-fibrotic effects of of TGFβ and PDGF in SSc fibroblasts. Selective inhibition of JNK by CC-930 exerted potent antifibrotic effects in vitro and in different models in vivo. JNK might thus be a novel molecular target for the treatment of fibrosis in SSc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2011-200412

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 60

Metadata

Authors
Reich, N., Tomcik, M., Zerr, P., Lang, V., Dees, C., Avouac, J., Palumbo, K., Horn, A., Akhmetshina, A., Beyer, C., Xie, W., Bennett, B. L., Distler, O., Schett, G., & Distler, J. H. W.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2012-05
Volume
71
Issue
5
Pages
737-745
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2142283590
Cited by
60
References
6
FWCI
4.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. https://app.cochat.ai/papers/10.1136/annrheumdis-2011-200412
The paper
Reich, N., Tomcik, M., Zerr, P., Lang, V., Dees, C., Avouac, J., Palumbo, K., Horn, A., Akhmetshina, A., Beyer, C., Xie, W., Bennett, B. L., Distler, O., Schett, G., & Distler, J. H. W. (2012). Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2011-200412

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.